Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aslan Licenses Array Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Aslan Licenses Array Cancer Drug

Aslan Pharmaceuticals and Array BioPharma have entered into a license agreement to develop Array’s HER2/EGFR inhibitor, ARRY-543, currently in Phase II development for solid tumors.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aslan Pharmaceuticals and Array BioPharma have entered into a license agreement to develop Array’s HER2/EGFR inhibitor, ARRY-543, currently in Phase II development for solid tumors.
Aslan will fund development through proof-of-concept, targeting gastric cancer in a development program conducted in Asia. Aslan will then find a global partner for Phase III development and commercialization and will share a portion of the proceeds. The agreement also includes an option for the two parties to negotiate to license a second undisclosed compound.

“Our partnership with Aslan provides a great opportunity to fund and advance the development of ARRY-543,” said Robert E. Conway, chief executive officer of Array BioPharma. “Aslan’s creative development strategy of leveraging Asia to conduct clinical development is particularly compelling for ARRY-543 due to the high prevalence of patients with gastric cancer in Asia. Aslan’s oncology team, led by Dr. Alan Barge, provides a rare combination of global and Asian drug development experience.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics